{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:44:11Z","timestamp":1790160251380,"version":"4.1.0"},"publisher-location":"Cham","reference-count":37,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319914381","type":"print"},{"value":"9783319914398","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-3-319-91439-8_5","type":"book-chapter","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T20:25:48Z","timestamp":1533155148000},"page":"109-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Ponatinib: A Third-Generation Inhibitor for the Treatment of CML"],"prefix":"10.1007","author":[{"given":"Julius","family":"Wehrle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"issue":"7","key":"5_CR1","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA et al (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108(7):2332\u20132338","journal-title":"Blood"},{"issue":"1","key":"5_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","volume":"102","author":"S Branford","year":"2003","unstructured":"Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102(1):276\u2013283","journal-title":"Blood"},{"issue":"27","key":"5_CR3","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","volume":"114","author":"S Branford","year":"2009","unstructured":"Branford S, Melo JV, Hughes TP (2009) Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114(27):5426\u20135435","journal-title":"Blood"},{"issue":"22","key":"5_CR4","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I et al (2012) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367(22):2075\u20132088","journal-title":"N Engl J Med"},{"key":"5_CR5","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE et al (2013) A phase 2 trial of ponatinib in Philadelphia chromosome\u2013positive leukemias. N Engl J Med 369:1783\u20131796","journal-title":"N Engl J Med"},{"key":"5_CR6","first-page":"64","volume":"100","author":"J Cortes","year":"2015","unstructured":"Cortes J, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C et al (2015) Ponatinib efficacy and safety in heavily pretreated leukemia patients: 3-year results of the PACE trial [abstract P234]. Haematologica 100:64","journal-title":"Haematologica"},{"issue":"6","key":"5_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","volume":"25","author":"T Darkow","year":"2007","unstructured":"Darkow T, Henk HJ, Thomas SK, Feng W, Baladi J-F, Goldberg GA et al (2007) Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 25(6):481\u2013496","journal-title":"Pharmacoeconomics"},{"issue":"20","key":"5_CR8","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H Lavallade de","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M et al (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 26(20):3358\u20133363","journal-title":"J Clin Oncol"},{"key":"5_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","volume":"48","author":"DJ Dorer","year":"2016","unstructured":"Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, Haluska FG (2016) Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res 48:84\u201391","journal-title":"Leuk Res"},{"issue":"14","key":"5_CR10","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031\u20131037","journal-title":"N Engl J Med"},{"issue":"23","key":"5_CR11","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408\u20132417","journal-title":"N Engl J Med"},{"key":"5_CR12","doi-asserted-by":"crossref","unstructured":"Falco VD, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M et al (2013) Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. J Clin Endocrinol Metab (Internet). 22 Mar 2013 (cited 29 Apr 2013). Available from \nhttp:\/\/jcem.endojournals.org\/content\/early\/2013\/03\/21\/jc.2012-2672","DOI":"10.1210\/jc.2012-2672"},{"issue":"10","key":"5_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/00008571-200310000-00003","volume":"13","author":"MD Floyd","year":"2003","unstructured":"Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K et al (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13(10):595\u2013606","journal-title":"Pharmacogenetics"},{"issue":"6","key":"5_CR14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1158\/1535-7163.MCT-10-1044","volume":"10","author":"JM Gozgit","year":"2011","unstructured":"Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK et al (2011) Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther 10(6):1028\u20131035","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"5_CR15","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","volume":"11","author":"JM Gozgit","year":"2012","unstructured":"Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI et al (2012) Ponatinib (AP24534), a multitargeted Pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 11(3):690\u2013699","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"5_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11864-013-0234-8","volume":"14","author":"P Jain","year":"2013","unstructured":"Jain P, Kantarjian H, Cortes J (2013) Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treat Options Oncol 14(2):127\u2013143","journal-title":"Curr Treat Options Oncol"},{"issue":"10","key":"5_CR17","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome\u2013positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10):3540\u20133546","journal-title":"Blood"},{"issue":"24","key":"5_CR18","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362(24):2260\u20132270","journal-title":"N Engl J Med"},{"issue":"9","key":"5_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12(9):841\u2013851","journal-title":"Lancet Oncol"},{"issue":"1","key":"5_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2141.1990.tb02533.x","volume":"74","author":"Y Kuwazuru","year":"1990","unstructured":"Kuwazuru Y, Yoshimura A, Hanada S, Ichikawa M, Saito T, Uozumi K et al (1990) Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis. Br J Haematol 74(1):24\u201329","journal-title":"Br J Haematol"},{"issue":"8","key":"5_CR21","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/cncr.20922","volume":"103","author":"T Lahaye","year":"2005","unstructured":"Lahaye T, Riehm B, Berger U, Paschka P, M\u00fcller MC, Kreil S et al (2005) Response and resistance in 300 patients with BCR-ABL\u2013positive leukemias treated with imatinib in a single center. Cancer 103(8):1659\u20131669","journal-title":"Cancer"},{"issue":"5","key":"5_CR22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","volume":"17","author":"JH Lipton","year":"2016","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S et al (2016) Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol 17(5):612\u201321","journal-title":"Lancet Oncol"},{"issue":"6","key":"5_CR23","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","volume":"101","author":"F-X Mahon","year":"2003","unstructured":"Mahon F-X, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al (2003) MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101(6):2368\u20132373","journal-title":"Blood"},{"issue":"6","key":"5_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.leukres.2006.12.003","volume":"31","author":"FE Nicolini","year":"2007","unstructured":"Nicolini FE, Chabane K, Tigaud I, Michallet M, Magaud J-P, Hayette S (2007) BCR-ABL mutant kinetics in CML patients treated with dasatinib. Leuk Res 31(6):865\u2013868","journal-title":"Leuk Res"},{"issue":"7","key":"5_CR25","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2019Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MWN (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110(7):2242\u20132249","journal-title":"Blood"},{"issue":"5","key":"5_CR26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16(5):401\u2013412","journal-title":"Cancer Cell"},{"issue":"11","key":"5_CR27","doi-asserted-by":"publisher","first-page":"E125","DOI":"10.1002\/ajh.23338","volume":"87","author":"S Redaelli","year":"2012","unstructured":"Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M et al (2012) Three novel patient-derived BCR-ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol 87(11):E125\u2013E128","journal-title":"Am J Hematol"},{"issue":"24","key":"5_CR28","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251\u20132259","journal-title":"N Engl J Med"},{"issue":"47","key":"5_CR29","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","volume":"22","author":"NP Shah","year":"2003","unstructured":"Shah NP, Sawyers CL (2003) Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22(47):7389\u20137395","journal-title":"Oncogene"},{"issue":"5","key":"5_CR30","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G et al (2011) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 118(5):1208\u20131215","journal-title":"Blood"},{"issue":"24","key":"5_CR31","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354(24):2531\u20132541","journal-title":"N Engl J Med"},{"issue":"12","key":"5_CR32","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE, Pirmohamed M (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104(12):3739\u20133745","journal-title":"Blood"},{"issue":"9305","key":"5_CR33","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","volume":"359","author":"N Bubnoff von","year":"2002","unstructured":"von Bubnoff N et al (2002) BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359(9305):487\u2013491","journal-title":"Lancet"},{"issue":"4","key":"5_CR34","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2004-06-2445","volume":"105","author":"N Bubnoff von","year":"2005","unstructured":"von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, S\u00e4nger J, Seipel P et al (2005) A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 105(4):1652\u20131659","journal-title":"Blood"},{"issue":"4","key":"5_CR35","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1182\/blood-2005-12-010132","volume":"108","author":"N Bubnoff von","year":"2006","unstructured":"von Bubnoff N et al (2006) Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108(4):1328\u20131333","journal-title":"Blood"},{"issue":"1","key":"5_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1747-0285.2010.01054.x","volume":"77","author":"T Zhou","year":"2011","unstructured":"Zhou T, Commodore L, Huang W-S, Wang Y, Thomas M, Keats J et al (2011) Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77(1):1\u201311","journal-title":"Chem Biol Drug Des"},{"issue":"4","key":"5_CR37","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1365-2141.2012.09085.x","volume":"157","author":"E Zirm","year":"2012","unstructured":"Zirm E, Spies-Weisshart B, Heidel F, Schnetzke U, B\u00f6hmer F-D, Hochhaus A et al (2012) Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation. Br J Haematol 157(4):483\u2013492","journal-title":"Br J Haematol"}],"container-title":["Recent Results in Cancer Research","Small Molecules in Hematology"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-91439-8_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T20:28:00Z","timestamp":1533155280000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-91439-8_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9783319914381","9783319914398"],"references-count":37,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-91439-8_5","relation":{},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}